Pembrolizumab plus Lenvatinib Shows Promising Activity but Substantial Toxicity as Second-Line Therapy After Nivolumab–Ipilimumab in Pleural Mesothelioma
In a single‑arm phase 2 cohort, pembrolizumab plus lenvatinib produced a 60% objective response rate in 20 patients with pleural mesothelioma progressing after first‑line nivolumab plus ipilimumab, but grade 3–4 toxicities were frequent (70%).